The Translational Genomics Research Institute and British Columbia Cancer Agency Branch | Date: 2015-03-23
The present invention relates compositions, methods and kits for characterizing the type of and screening for the existence or predisposition for small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). The invention also relates to a method of treating a mammalian subject having SCCOHT or a predisposition for SCCOHT.
The Translational Genomics Research Institute and Northern Arizona University | Date: 2016-07-29
The present technology provides methods and kits that may be used to detect and quantify the presence of Coccidioides species. The methods include quantification real-time PCR assays, and the kits and compositions include oligonucleotides used as primers and probes.
The Translational Genomics Research Institute | Date: 2015-10-23
The present invention is directed to methods for treating cancer in a subject, such as a cancer of the endocrine system. In some aspects, the method includes administering to the subject one or more of a polo-like kinase 1 inhibitor, a mouse double minute 2 inhibitor, and/or a mitotic catastrophe inducing compound. In other aspects, the method includes measuring an expression level of one or more markers, including caspase 8 and caspase 9, to assess the functionality of the caspase cascade in the subject.
The Translational Genomics Research Institute | Date: 2016-06-20
Methods of tests that assess the expression of DPC4 (SMAD4) to identify subjects with pancreatic cancer that are likely or unlikely to respond to treatment with BTK inhibitors; methods of treating subjects based on identification of the subjects as likely to respond to treatment with BTK inhibitors; therapeutic targets for cancers, particularly cancers with inactivated DPC4 gene or protein; methods of screening of new therapeutic agents using the target; pharmaceutical composition comprising BTK inhibitors, such as PCI-32765 or derivatives thereof, for cancer treatment; and kits that facilitate the performance of the methods are disclosed.
The Translational Genomics Research Institute | Date: 2015-03-25
Embodiments of the invention provide methods of creating clinical models for different forms of metastatic cancer. The methods may include obtaining samples from subjects with metastatic cancer, determining an allelic status of one or more markers in the samples (e.g., creating a molecular profile of the subjects cancer), and using model organisms with subject-derived xenografts for treatment selection.
The Translational Genomics Research Institute | Date: 2016-07-07
The invention encompasses methods used in the sensitization and treatment of cancer based upon the expression of SGEF.
The Translational Genomics Research Institute and Northern Arizona University | Date: 2016-07-20
Embodiments of the invention provide a method of detecting one or more strains of Klebsiella pneumoniae. The method may include forming a plurality of mixtures for nucleic amplification. The method can include amplification of specific sequences within the K. pneumonia genome that can provide definitive information to distinguish between one or more types or strains of K. pneumonia.
The Translational Genomics Research Institute and Mayo Foundation For Medical Education And Research | Date: 2016-03-14
The invention encompasses methods of treating a patient with cancer, such as glioblastoma. The methods may include the administration of one or more pharmaceutical compositions that are capable of inhibiting TROY to treat the patient with cancer.
The Translational Genomics Research Institute | Date: 2016-08-23
The Translational Genomics Research Institute and University of Washington | Date: 2016-03-31
Diagnostic and therapeutic applications for endometrial cancer are described. The diagnostic and therapeutic applications are based on certain activation mutations in the FGFR2 gene and its expression products. The present invention is directed to nucleotide sequences, amino acid sequences, probes, and primers related to FGFR2 activation mutants and kits comprising these mutants to diagnosis and classify endometrial cancer in a subject.